Known targets — ChEMBL curated mechanism
GRIA1GRIA2GRIA3GRIA4GRIK1GRIK2GRIK3GRIK4GRIK5
The experimentally established mechanism targets of Selurampanel. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HAVCR2 | Q8TDQ0 | 1/20 | 0.34 |
| ▸ | IDH1 | O75874 | 3/20 | 0.34 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.33 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.33 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.33 |
| ▸ | BRD4 | O60885 | 1/20 | 0.32 |
| ▸ | AKT1 | P31749 | 1/20 | 0.31 |
| ▸ | IMPDH2 | P12268 | 2/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | METAP2 | P50579 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Selurampanel SCHEMBL30259242 | 1.00 | HAVCR2 (0.34) | HAVCR2IDH1TLR9TLR8TLR7 | |
| SCHEMBL1661007 | 0.92 | IDH1 (0.35) | HAVCR2IDH1TLR9TLR8TLR7 | |
| SCHEMBL1661254 | 0.91 | HAVCR2 (0.34) | HAVCR2IDH1BRD4CYP1A2METAP2 | |
| SCHEMBL1067354 | 0.89 | USP1 (0.36) | HAVCR2IDH1 | |
| SCHEMBL12180698 | 0.86 | ALDH1A1 (0.34) | BRD4 | |
| SCHEMBL1661441 | 0.85 | ALDH1A1 (0.36) | IMPDH2CYP1A2 | |
| SCHEMBL1663156 | 0.85 | HAVCR2 (0.35) | HAVCR2BRD4IMPDH2CYP1A2METAP2 | |
| SCHEMBL1661230 | 0.84 | CYP1A2 (0.39) | HAVCR2BRD4CYP1A2METAP2 | |
| SCHEMBL1001057 | 0.83 | CYP1A2 (0.36) | HAVCR2IDH1BRD4CYP1A2METAP2 | |
| SCHEMBL1661264 | 0.83 | HAVCR2 (0.34) | HAVCR2IDH1BRD4CYP1A2METAP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 233 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122075705-A | Application of AMPA receptor antagonist in preparation of medicine for treating gastric cancer peritoneal metastasis | — | 2026-05-26 | — | — | CN | claimed |
| EP-4370202-B1 | XENON GAS FOR USE IN THE TREATMENT OF GLIOMAS | UNIV HEIDELBERG (DE) | 2026-03-18 | — | — | EP | claimed |
| US-20250382291-A1 | SUBSTITUTED PYRROLO[2,3-b]PYRIDINES FOR SUPPRESSING TOXIC ENDOPLASMIC RETICULUM STRESS | UNIV COLUMBIA (US) | 2025-12-18 | — | — | US | claimed |
| US-20250032503-A1 | USE OF APREPITANT FOR TREATING ALZHEIMER'S DISEASE | HOTH THERAPEUTICS, INC. | 2025-01-30 | — | — | US | claimed |
| US-20250000896-A1 | Xenon Gas for Use in the Treatment of Gliomas | Universität Heidelberg (DE) | 2025-01-02 | — | — | US | claimed |
| CN-113286777-B | Compounds, compositions and methods for modulating iron death and treating excitotoxic disorders | 纽约市哥伦比亚大学理事会 | 2024-10-29 | — | — | CN | claimed |
| US-20240156790-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR MODULATING FERROPTOSIS AND TREATING EXCITOTOXIC DISORDERS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2024-05-16 | — | — | US | claimed |
| EP-4347605-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR MODULATING FERROPTOSIS AND TREATING EXCITOTOXIC DISORDERS | The Trustees of Columbia University in the City of New York (US) | 2024-04-10 | — | — | EP | claimed |
| CN-117677623-A | Compounds, compositions and methods for modulating iron death and treating excitotoxic disorders | 纽约市哥伦比亚大学理事会 | 2024-03-08 | — | — | CN | claimed |
| US-20240016766-A1 | PHARMACEUTICAL COMPOSITION FOR TREATMENT OF INNER EAR DISORDERS THROUGH LOCAL ADMINISTRATION IN THE TYMPANIC AREA | AB SCIENCE (FR) | 2024-01-18 | — | — | US | claimed |
| EP-2585070-A1 | USE OF 1H-QUINAZOLINE-2,4-DIONES | Novartis AG (CH) | 2013-05-01 | — | — | EP | claimed |
| US-20130096145-A1 | Use of 1H-quinazoline-2,4-diones | NOVARTIS AG (CH) | 2013-04-18 | — | — | US | claimed |
| US-20130090346-A1 | Use of 1H-quinazoline-2,4-diones | NOVARTIS AG (CH) | 2013-04-11 | — | — | US | claimed |
| WO-2013036224-A1 | USE OF 1H-QUINAZOLINE- 2, 4 -DIONES FOR USE IN THE PREVENTION OR TREATMENT PHOTOSENSITIVE EPILEPSY | NOVARTIS AG (CH) | 2013-03-14 | — | — | WO | claimed |
| EP-2490691-A1 | USE OF 1H-QUINAZOLINE-2,4-DIONES | Novartis AG (CH) | 2012-08-29 | — | — | EP | claimed |
| EP-1871749-B1 | Selurampanel | NOVARTIS AG (CH) | 2012-08-01 | — | — | EP | claimed |
| US-20120122903-A1 | 1-H-QUINAZOLINE-2, 4-DIONES FOR USE IN THE TREATMENT OF NEURONAL CEROID LIPOFUSCINOSIS | NOVARTIS AG (CH) | 2012-05-17 | — | — | US | claimed |
| WO-2011161249-A1 | USE OF 1H-QUINAZOLINE-2,4-DIONES | NOVARTIS AG (CH) | 2011-12-29 | — | — | WO | claimed |
| WO-2011048150-A1 | USE OF 1H-QUINAZOLINE-2,4-DIONES | NOVARTIS AG (CH) | 2011-04-28 | — | — | WO | claimed |
| US-7655666-B2 | Substituted 1H-quinazoline-2,4-diones useful as AMPA receptor ligands | NOVARTIS AG (CH) | 2010-02-02 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130090346-A1 | Use of 1H-quinazoline-2,4-diones | GRIK2, GRIK1, GRIK4 | HAVCR2 1866/4885IDH1 2214/4885TLR9 810/4885 |
| US-20130096145-A1 | Use of 1H-quinazoline-2,4-diones | GRM1, GRIK2, GRIK1 | HAVCR2 3857/4885IDH1 2399/4885TLR9 2332/4885 |
| US-20240156790-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR MODULATING FERROPTOSIS AND TREATING EXCITOTOXIC DISORDERS | AIFM2, GPX1, SLC7A11 | HAVCR2 357/4885IDH1 122/4885TLR9 637/4885 |
| US-20250032503-A1 | USE OF APREPITANT FOR TREATING ALZHEIMER'S DISEASE | TACR1, ACHE, TACR2 | HAVCR2 838/4885IDH1 4076/4885TLR9 1862/4885 |
| US-20250382291-A1 | SUBSTITUTED PYRROLO[2,3-b]PYRIDINES FOR SUPPRESSING TOXIC ENDOPLASMIC RETICULUM STRESS | HSPA5, ATP2A1, DNAJC10 | HAVCR2 4006/4885IDH1 1892/4885TLR9 4234/4885 |
| US-20120122903-A1 | 1-H-QUINAZOLINE-2, 4-DIONES FOR USE IN THE TREATMENT OF NEURONAL CEROID LIPOFUSCINOSIS | CLN6, GBA1, GBA2 | HAVCR2 3421/4885IDH1 2878/4885TLR9 1487/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.